Please login to the form below

Not currently logged in

Moderna’s COVID-19 vaccine generates strong immune response in older adults

New data builds on initial data read-out announced in August

Results from a phase 1 study of Moderna’s COVID-19 vaccine candidate have shown promise in older adults, with the vaccine generating a strong immune response in this population.

The results from the study supported by the US National Institutes of Allergy and Infectious Diseases (NIAID) were published in the New England Journal of Medicine yesterday.

The new data builds and expands on the initial results released n August detailing the efficacy of Moderna’s mRNA-1273 vaccine in 20 adults between the ages 56-71 and older.

The updated results come from an expansion of the trial which included a larger proportion of older adults, comprising 20 adults aged 56-70 years old and 20 adults aged 71 years and older.

Ten volunteers in each age group received a lower dose of the vaccine – 25 µg – and the other ten received a higher dose of 100 µg. Participants then received a second dose of the same vaccine at the same dosage a month later.

The researchers found that the mRNA-1273 vaccine was well-tolerated in this older age group, with participants exhibiting a good immune response following administration of two doses of the vaccine.

Notably, the blood of participants vaccinated with Moderna’s vaccine contained robust binding and neutralising antibodies against the SARS-CoV-2 virus, which causes COVID-19. The presence of neutralising antibodies is an important early indicator of efficacy at this stage of clinical testing.

More importantly, the levels observed in older participants was comparable to younger volunteers – experts have raised concerns that a potential vaccine against COVID-19 may not be as effective in this population, as the elderly are likely to have a weaker immune system compared to younger people.

However, Moderna has quelled some of these fears with the expanded trial results, especially given that the vaccine was deemed safe to use, with only some older volunteers experiencing transient adverse events including fever and fatigue after vaccination.

“Given the increased morbidity and mortality of COVID-19 in older and elderly adults, this data gives us optimism in demonstrating mRNA-1273’s protection in this population, which is being evaluated in the phase 3 COVE study,” said Tal Zaks, chief medical officer of Moderna.

Following the positive results, the study will continue to follow the older participants for approximately a year to monitor the long-term effects of the vaccine. The data also supports further testing of the investigational vaccine candidate in older adults in an ongoing phase 3 trial.

Article by
Lucy Parsons

30th September 2020

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...